ETHOHEPTAZINE

US Previously Marketed

First approved in 1957

Details

Stereochemistry	RACEMIC
Molecular Formula	C16H23NO2
Molecular Weight	261.3593
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)C1(CCCN(C)CC1)C2=CC=CC=C2

InChI

InChIKey=WGJHHMKQBWSQIY-UHFFFAOYSA-N

InChI=1S/C16H23NO2/c1-3-19-15(18)16(14-8-5-4-6-9-14)10-7-12-17(2)13-11-16/h4-6,8-9H,3,7,10-13H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C16H23NO2
Molecular Weight	261.3593
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: ISBN: 978-1-4899-6748-0, Ronald J. Tallarida Ph.D., 'TOP 200: A compendium of pharmacologic and therapeutic information on the most widely prescribed drugs in America' (1982), p. 101, Retrieved from https://link.springer.com/book/10.1007/978-1-4899-6746-6

Ethoheptazine is an analgesic, which belongs to the proheptazine group. It was used either alone (Zactane trade name) or in combination with meprobamate and aspirin (Equagesic) for the pain relief in patients with headache or musculoskeletal disorders. Currently all mediactions containing ethoheptazine are withdrawn from the market. The exact target of ethoheptazine is unknow, but it is believed that it may have modulatory effect on opioid receptors.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Opioid receptors; mu/kappa/delta 33 Target ID: CHEMBL2095181 Sources: https://www.google.co.jp/patents/WO2006138186A1	Modulator 828

Conditions

Condition	Modality	Targets	Highest Phase	Product
Musculoskeletal disorders 10 Sources: Tallarida, R.J. (1982) TOP 200: A compendium of pharmacologic and therapeutic information on the most widely prescribed drugs in America, page 101, retrieved from https://books.google.ru/books?id=qHv1BwAAQBAJ	Palliative		Approved 8429	EQUAGESIC Approved Use Equagesic is possibly effective in the treatment of pain accompained by tension and anxiety in patients with musculoskeletal disease or tension headache.
Tension headache 3 Sources: Tallarida, R.J. (1982) TOP 200: A compendium of pharmacologic and therapeutic information on the most widely prescribed drugs in America, page 101, retrieved from https://books.google.ru/books?id=qHv1BwAAQBAJ	Primary		Approved 8429	EQUAGESIC Approved Use Equagesic is possibly effective in the treatment of pain accompained by tension and anxiety in patients with musculoskeletal disease or tension headache.

Doses

Dose	Population	Adverse events
100 mg 6 times / day multiple, oral Recommended Dose: 100 mg, 6 times / day Route: oral Route: multiple Dose: 100 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/13469802 Page: p.416	unhealthy n = 83 Health Status: unhealthy Condition: Pain Sex: F Population Size: 83 Sources: https://pubmed.ncbi.nlm.nih.gov/13469802 Page: p.416	Sources: https://pubmed.ncbi.nlm.nih.gov/13469802 Page: p.416

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY571131	https://www.001chemical.com/chem/77-15-6
ABI Chem	AC1L1MLL
AK Scientific	2032AC
AK Scientific, Inc. (AKSCI)	2032AC	http://www.aksci.com/item_detail.php?cat=2032AC
AN PharmaTech	AN-5629
Ambinter	Amb22002573	http://www.ambinter.com/reference/22002573
Aurora Fine Chemicals LLC	A30.257.838	http://online.aurorafinechemicals.com/info?ID=A30.257.838
BLD Pharm	BD127693	http://www.bldpharm.com/products/77-15-6.html
BePharm Ltd.	B127693
ChemMol	49400380	http://www.chemmol.com/chemmol/49400380.html
ChemMol	99151439	http://www.chemmol.com/chemmol/99151439.html
ChemTik	CTK6F4564
Chemhere	Achem589535
Chemieliva Pharmaceutical Co., Ltd	PBCM0825114
Compound Cloud	23165
Compound Cloud	6469
Molcore	MC571131	https://www.molcore.com/product/77-15-6
NCI Plated 2007	400484
Norris Pharm	NSZB-A224720
NovoSeek	6469
Oxchem Corporation	AX8127693
Smolecule	S600803	https://www.smolecule.com/products/s600803
THE BioTek	bt-433592	https://www.thebiotek.com/product/others/bt-433592
Toronto Research Chemicals	E678280
ZINC	ZINC000000000268	http://zinc15.docking.org/substances/ZINC000000000268
ZINC	ZINC000001593302	http://zinc15.docking.org/substances/ZINC000001593302

PubMed

Title	Date	PubMed
Methods in evaluating ethoheptazine and ethoheptazine combined with aspirin.	1958 Apr 12	13525157
Clinical comparison of ethoheptazine and aspirin with other analgesic combinations.	1961 Mar	13712506
Treatment of musculoskeletal pain and associated anxiety with an ethoheptazine-aspirin-meprobamate combination (equagesic): a controlled study.	1974 Sep	4214668
Effects of propoxyphene, ethoheptazine, and azabicyclane on schedule-controlled responding: attenuation by pentobarbital but not naloxone.	1979	44372
Determination of ethoheptazine in human post mortem material.	1983 Oct 14	6643621
Fixed drug eruption masquerading as herpes simplex labialis.	1984 Sep 29	6236869
Mefenamic acid, chlormezanone-paracetamol, ethoheptazine-aspirin-meprobamate: a comparative study in acute low back pain.	1987 Feb	2960369

Patents

Sample Use Guides

In Vivo Use Guide

The usual dose is 1 or 2 tablets three or four times daily.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:03:47 GMT 2023` Edited by `admin` on `Fri Dec 15 18:03:47 GMT 2023`
Record UNII	3A4G3A848U
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ETHOHEPTAZINE

Official Name

English

ETHOHEPTAZINE [VANDF]

Common Name

English

ethoheptazine [INN]

Common Name

English

ETHOHEPTAZINE [MI]

Common Name

English

Ethoheptazine [WHO-DD]

Common Name

English

ETHOHEPTAZINE [HSDB]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C67413